

# Montana Healthcare Programs Drug Utilization Review Board Agenda

## Hosted by Mountain Pacific Quality Health

June 24, 2026

1-5 PM

**Virtual Call Only**

**Register in advance for this meeting:**

<https://events.teams.microsoft.com/event/168aa532-185c-4a42-9545-d49e75b0c4ac@1f053f7a-e47d-43fd-9182-8507c9ff10c7> [events.teams.microsoft.com]

1. Introductions

2. Public Comment- 15 minutes

Public Comment will be permitted on items over which the DUR Board has jurisdiction. All persons wishing to speak through the video conferencing platform must notify the Department by submitting their name and topic they wish to speak on via <https://forms.office.com/g/EkPyKbJYTv> by **noon** the day prior to the meeting. Individual comment will be limited to a maximum of 3 minutes per person and is subject to further limitations depending on the number of speakers (15 minutes divided by total speakers).

Due to time constraints, all persons are encouraged to provide written comment, especially those providing clinical information, to allow the board adequate time to review and research. Please email written comments and/or clinical information, with a statement indicating that it is public comment, to [PDL@mt.gov](mailto:PDL@mt.gov) at least 7 days prior to the meeting. Please limit clinical information to 2 pages and to new information since last review. New peer-reviewed randomized comparative controlled trials or randomized controlled trials with true health outcomes are most helpful. Please do not provide any pricing information. Materials submitted less than 7 days prior to the meeting, in excess of 2 pages, and/or including pricing information will not be included in the board members' meeting packets.

3. Meeting Minutes

- May 2026 PDL Board Meeting Minutes

4. Department Update

5. PA Criteria Update

- Age Extensions and Language Updates
  - Rinvoq® FDA labeling update
  - Stelara® age expansion
  - Tziel® age expansion
  - Xeljanz® age expansion
- New Indication/Formulation
  - Dupixent® new indication and age expansion
  - Sotyktu® new indication

6. New Drugs

- Icotyde™ (icotrokinra)
- Nereus® (tradipitant)

7. Follow up from PDL meetings

- Spravato® review of counseling requirements
- Antifungals:
  - Griseofulvin
  - Ketoconazole
- Lipid lowering agents:
  - Evkeeza® age expansion and criteria review
  - Leqvio® new indication
  - Praluent® update and criteria review
  - Repatha® criteria review

8. PA Criteria removal

- Pulmozyme®
- Benlysta®
- Calcitonin-salmon (nasal)